Pharma: Page 63
-
Courtesy of Novavax, Australian Broadcasting Corporation
Novavax boosts coronavirus vaccine manufacturing capacity as key trial nears
The Serum Institute of India, a go-to partner for coronavirus vaccine makers, will help Novavax boost capacity to levels matching its larger rivals.
By Jonathan Gardner • Sept. 15, 2020 -
AstraZeneca, Oxford vaccine study allowed to restart in UK
Six days after a worrisome illness in a U.K. study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume.
By Ben Fidler • Sept. 12, 2020 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineTop 5 stories from BioPharma Dive
Looming patent expiries this decade and intensifying competition from China are forcing drugmakers to adapt, while new opportunities open up in oncology and in neuroscience.
By BioPharma Dive staff -
GSK inhaler locks down a coveted approval in asthma
The approval helps differentiate Trelegy Ellipta, a three-drug treatment for COPD and, now, asthma, in the crowded respiratory drug market.
By Jacob Bell • Sept. 10, 2020 -
Sanofi's hemophilia drug comes into focus as delays hit a key competitor
With BioMarin's gene therapy sidelined, attention is turning to other drugs, including one Sanofi acquired when it paid $11.6 billion for Bioverativ.
By Jacob Bell • Sept. 10, 2020 -
Getty Images
Sponsored by ZSThe voice of the customer, and how pharma can respond
ZS surveyed more than 500 physicians, 500 patients and 30 healthcare administrators to gather their current thoughts on care delivery, telemedicine and pharma's potential role during the COVID-19 pandemic.
By Yasasvi Popuri, Jay Lichtenstein & Ganesh Vedarajan • Sept. 10, 2020 -
Jacob Bell/BioPharma Dive
Merck takes aim at Pfizer with pneumonia vaccine data
Results from two Phase 3 studies put Merck in position to ask for FDA approval of its shot later this year. Pfizer may not be far behind with a rival product.
By Jonathan Gardner • Sept. 9, 2020 -
Danielle Ternes/BioPharma Dive
Deep DiveHow biotech and pharma companies pay their CEOs, and their workers
The median CEO of 231 drug companies analyzed by BioPharma Dive earned 50% more last year than in 2017, a leap that far outpaced the more modest pay gains among employees.
By Ned Pagliarulo • Sept. 9, 2020 -
Jacob Bell/BioPharma Dive
Merck details cough drug data, raising questions about its potential
Merck's drug could be the first-ever treatment for chronic cough, a condition that afflicts millions. But side effects and modest efficacy may limit its use.
By Jonathan Gardner • Sept. 8, 2020 -
Coronavirus vaccine makers vow to wait for data before seeking approval
In an unusual letter, the heads of nine top vaccine developers pledged to "stand with science" and only move forward with approval applications if warranted by clinical results.
By Ben Fidler • Sept. 8, 2020 -
Sanofi, GSK, racing to catch up, begin first human study of coronavirus vaccine
The two vaccine developers are betting their proven technology will lead to a more potent shot than others, making up for their slower pace of testing.
By Ben Fidler • Sept. 3, 2020 -
Courtesy of Sanofi
Sanofi ends research of arthritis drug as coronavirus treatment
Kevzara failed to shorten hospital stays among patients severely sick with COVID-19, study results showed, further dimming hopes that drugs similar to it could help combat the disease.
By Jonathan Gardner • Sept. 1, 2020 -
AstraZeneca, vowing it won't cut corners, begins large US study of coronavirus vaccine
Amid reports the U.S. might fast-track AstraZeneca and the University of Oxford's experimental shot, the company pledged to "follow the science."
By Ben Fidler • Sept. 1, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel coronavirus SARS-CoV-2" [Microscope image]. Retrieved from https://www.flickr.com/photos/nihgov/49565158908/in/album-72157713108522106/.
Vir, GSK push coronavirus antibody drug straight into mid-stage tests
The two companies, chasing rival treatments from Eli Lilly, Regeneron and more, aim to produce their first study results by the end of the year.
By Jonathan Gardner • Aug. 31, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
CanSino said to seek early authorization of coronavirus vaccine
The reported talks between CanSino and several countries highlight the urgency with which governments are operating to secure supply of experimental coronavirus vaccines.
By Jonathan Gardner • Aug. 28, 2020 -
Permission granted by BioNTech SE
Moderna's vaccine may have an edge when immunization programs roll out
A rival shot from Pfizer and BioNTech needs to be stored at colder temperatures and doesn't last as long in a refrigerator, which may limit its use.
By Jonathan Gardner • Aug. 26, 2020 -
Moderna says its coronavirus vaccine sparks immune response in older people
An initial look at the vaccine's effects on the elderly shows those in their 70s had similar responses to those under 55, Moderna told a government panel.
By Jonathan Gardner • Aug. 26, 2020 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
AstraZeneca's coronavirus antibody drug cocktail begins human tests as rivals slip
The British pharma has started a Phase 1 trial amidst reports that competing programs from Regeneron and Eli Lilly haven't met their projected timelines.
By Ben Fidler • Aug. 25, 2020 -
Permission granted by Novartis
Novartis set to take on Roche as FDA clears first at-home, injectable MS drug
Kesimpta, a new multiple sclerosis drug from Novartis, works the same way as Roche's blockbuster Ocrevus, but patients can take it without leaving home.
By Ben Fidler • Aug. 20, 2020 -
Courtesy of Eli Lilly
Lilly doubles down on Innovent cancer drug in immunotherapy push
The Indianapolis pharma paid $200 million to gain most of the rights to Tyvyt, a checkpoint blocker that could help it compete with Merck, Roche and others.
By Ben Fidler • Aug. 18, 2020 -
Permission granted by Gilead Sciences
Gilead expands Tango alliance, continuing a busy year of cancer deals
A $145 million payment to broaden a partnership with Tango Therapeutics is the latest in a series of deals Gilead has made to grow its oncology business.
By Jonathan Gardner • Aug. 18, 2020 -
Courtesy of Sanofi
Sanofi, seeking control of key drug, to buy Principia for $3.7B
The acquisition significantly increases Sanofi's bet on Principia's chief asset, an experimental drug for multiple sclerosis now in late-stage testing.
By Ned Pagliarulo • Aug. 17, 2020 -
Roche wins FDA approval for first self-administered biologic for rare eye disease
Enspryng is the second drug OK'd in three months for an autoimmune disorder that causes blindness and impaired mobility, but it's the only one that patients can take at home.
By Jonathan Gardner • Aug. 17, 2020 -
Europe, trailing US, UK, reaches first coronavirus vaccine deal
Both the U.S. and U.K. have aggressively signed preorder deals with vaccine developers. An agreement with AstraZeneca is the EU's first.
By Ned Pagliarulo • Aug. 14, 2020 -
Bristol Myers pledges to spend $300M on addressing racial, health disparities
The drugmaker aims to double Black and Latinx representation in its executive ranks, among other commitments.
By Kristin Jensen • Aug. 12, 2020 -
Moderna gets $1.5B from US for coronavirus vaccine supply
The U.S. has already invested heavily in Moderna's shot, having previously committed $1 billion to fund clinical trials and manufacturing scale-up.
By Ned Pagliarulo • Aug. 11, 2020
Previous
